2 months ago
PTGX
AnalystsRichard LawRichard Law's Stock Forecasts
AnalystsRichard Law
Sectors:
Industries:
Analyst Ranking
Top 19%
#1009 out of 5548 analysts
Average Return
+7.04%
Win Rate
40%19 out of 48
Risk vs Reward
Poor
Good
Richard Law's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Olema Pharmaceuticals IncOLMA | +234.19% | $3.89 | $13.00 | 2023-03-10 - 2024-03-08 | Buy |
Olema Pharmaceuticals IncOLMA | +204.17% | $4.56 | $13.87 | 2023-02-22 - 2024-02-21 | Buy |
Olema Pharmaceuticals IncOLMA | +201.78% | $4.50 | $13.58 | 2025-05-14 - 2026-05-13 | Strong Buy |
Mineralys Therapeutics IncMLYS | +173.14% | $10.20 | $27.86 | 2025-02-13 - 2026-02-12 | Strong Buy |
Merus NvMRUS | +116.39% | $44.36 | $95.98 | 2024-11-21 - 2025-11-20 | Strong Buy |
Richard Law Analyst Color
Get additional color on Richard Law's coverage of popular stocks
10 months ago
OLMA
a year ago
OLMA
a year ago
NUVL
Richard Law's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Rocket Pharmaceuticals IncRCKT | 5 | Hold | $4.00 | +74.67% | Upgrades | 17 days ago |
Bicara Therapeutics IncBCAX | 3 | Hold | $20.00 | +17.16% | Maintains | 2 months ago |
Protagonist Therapeutics IncPTGX | 2 | Strong Buy | $186.00 | +34.36% | Upgrades | 2 months ago |
Hemab Therapeutics Holdings IncCOAG | 1 | Strong Buy | $36.00 | +4.65% | Initiates Coverage On | 5 months ago |
Arcus Biosciences IncRCUS | 2 | Strong Buy | $34.00 | +83.39% | Maintains | 6 months ago |
Viridian Therapeutics IncVRDN | 6 | Strong Buy | $31.00 | +38.58% | Maintains | 7 months ago |
Olema Pharmaceuticals IncOLMA | 8 | Strong Buy | $27.00 | +321.22% | Maintains | 7 months ago |
Celldex Therapeutics IncCLDX | 4 | Hold | $34.00 | +16.24% | Maintains | 8 months ago |
Moonlake ImmunotherapeuticsMLTX | 5 | Strong Sell | $10.00 | -15.61% | Downgrades | 9 months ago |
Crinetics Pharmaceuticals IncCRNX | 2 | Strong Buy | $67.00 | -21.13% | Upgrades | 9 months ago |
Nuvalent IncNUVL | 1 | Strong Buy | $135.00 | +8.91% | Maintains | a year ago |
Arcutis Biotherapeutics IncARQT | 2 | Hold | $29.00 | -7.05% | Maintains | a year ago |
Mineralys Therapeutics IncMLYS | 7 | Strong Buy | $52.00 | N/A | Maintains | a year ago |
Silence Therapeutics PLCSLN | 3 | Strong Sell | $3.00 | N/A | Maintains | a year ago |
Viking Therapeutics IncVKTX | 1 | Hold | $30.00 | N/A | Initiates Coverage On | 2 years ago |
Merus NvMRUS | 1 | Strong Buy | $73.00 | N/A | Initiates Coverage On | 2 years ago |
Monte Rosa Therapeutics IncGLUE | 4 | Hold | $11.00 | N/A | Reiterates | 3 years ago |
Verve Therapeutics IncVERV | 2 | Hold | $31.00 | N/A | Reiterates | 3 years ago |
Beam Therapeutics IncBEAM | 3 | Hold | $47.00 | N/A | Maintains | 3 years ago |
Crispr Therapeutics AgCRSP | 6 | Hold | $63.00 | N/A | Maintains | 3 years ago |
Kymera Therapeutics IncKYMR | 8 | Hold | $37.00 | N/A | Maintains | 3 years ago |
Intellia Therapeutics IncNTLA | 5 | Buy | $76.00 | N/A | Reiterates | 3 years ago |
Q32 Bio IncQTTB | 4 | Hold | $36.00 | N/A | Reiterates | 3 years ago |
Editas Medicine IncEDIT | 3 | Hold | $14.00 | N/A | Maintains | 3 years ago |
Arvinas IncARVN | 4 | Buy | $61.00 | N/A | Reiterates | 3 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.